Nonhuman Primate Reagent Resource - NHPRR

NHPRR Journal Club Kickoff Therapies targeting CD154-CD11b/CD40 in Transplantation We kicked off our Fall Journal Club earlier this year to give our interns, Alexander Appiah Kubi and Alex Lourenco, the opportunity to present their insights on a critical study in the field of transplantation. Our latest discussion focused on the manuscript titled "CD11b is a novel alternate receptor for CD154 during alloimmunity" by Danya Liu and Mandy L. Ford. This study explores the CD40-CD154 pathway, long known for its role in promoting transplant survival. However, the research introduces a significant finding: CD154 interactions with CD11b are crucial in mouse graft rejection. 🔍 Key Takeaways from Our Intern Critics: Alex Kubi highlighted the study's approach to understanding how blocking both CD154-CD40 and CD154-CD11b interactions can improve transplant outcomes. "It was fascinating to learn how these interactions drive immune responses and how targeting both pathways could offer a more effective strategy for preventing graft rejection." Alex Lourenco appreciated how the study highlighted the complexities of immunotherapy research, especially the importance of controlling variables in experimental design. "As someone new to CD154's role in immune responses, I had to dig into the methods, like flow cytometry and the choice of animal models, to fully understand the study (...) I hope these findings can eventually lead to improved outcomes in human organ transplants." 💡 Why This Matters (according to our Alexes): The study reveals that targeting both CD154-CD40 and CD154-CD11b interactions can significantly enhance transplant survival, providing a potential path to better clinical outcomes. The CD40-CD154 (CD40L) pathway is critical to successful xenotransplantation, as demonstrated by over 70 publications involving our anti-CD154 and anti-CD40 antibodies. As we continue to explore these pathways, we aim to translate these preclinical findings into clinical success, advancing the field of transplant immunotherapy. Congrats to the authors! 🔗 Link to the manuscript: https://lnkd.in/eHHk9x35 #NHPRR #Immunotherapy #Transplantation #JournalClub #CD11b #CD154 #BiomedicalResearch #OrganTransplant #ScienceInnovation #InternInsights

📰 NHPRR Partners with mAbsolve to Launch STR-Enhanced Antibodies Highlights: 🐒 NHPRR's tailored pipeline addresses researchers’ needs with critical human disease models 🎯 Our products are designed to maximize translatable findings with species-specific biology in mind ✨ STR optimization attenuates Fc effector function in NHPs and humans, enhancing precision, safety, and translatability 💡Let the best science flourish! At the NHPRR, we specialize in developing therapies for critical nonhuman primate disease models. Our preclinical biomedical products are engineered to translate breakthroughs across human and nonhuman species, considering species-specific biology in every design (epitope, pathway, effector function conservation). Today, we celebrate a milestone—partnering with mAbsolve to incorporate ‘STR’ mutations into our antibodies. This ensures targeted action without unintended immune responses, boosting rigor, effectiveness, and safety. By decreasing Fc-mediated interference (hello Fc-block!) and enhancing the signal-to-noise ratio, STR-enhanced antibodies will produce more robust and reproducible scientific findings. Expect many STR-enhanced antibodies soon! This partnership enhances our resource capabilities and expands the potential for our products to be licensed and clinically developed, following the success of our previous contributions. This aligns directly with our core commitment to facilitate the translation of great scientific ideas into human health! About Nonhuman Primate Reagent Resource - NHPRR The NHPRR has been a leader in advancing biological research with nonhuman primate models for 25 years. By distributing high-quality, specialized research antibodies, NHPRR has supported over 2,000 NIH grants, enabling fundamental discoveries such as the role of CD40-CD40L therapies in pig-to-primate xenotransplantation, the study of AIDS virus reservoirs in macaques, the critical role of CD8+ T cells in elite control of AIDS, and the testing of immunological responses in early monkey models of COVID, contributing to the development of human vaccines. Visit www.nhpreagents.org for more information. About mAbsolve Ltd. mAbsolve founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Our STR technology is the only truly silent Fc. Visit www.mabsolve.com for more information. Contacts Diogo Magnani Director, NHPRR [email protected] Ian Wilkinson Chief Scientific Officer, mAbsolve [email protected]

🌞 We took a break from social media this summer, but we were anything but idle! From lively gatherings to the MBI Summer Bash, intense Fall planning, and manuscript writing, our team stayed busy and had a blast along the way. 📸 We also had the privilege of participating in NIH conferences and dedicated time to training our 2024 interns. It’s been a season of planning, learning, and community. Stay tuned to our Fall plans! We will share our Journal Club online for the first time, so be ready to pitch your paper suggestions! #SummerRecap #MBISummerBash #NonhumanPrimateResearch

Thanks for the great visit, Ricardo Padua! It was a pleasure to hear you and see your beautiful (and hot!) structures in astonishing detail (for the folks that missed it, here is a link to some of his published work: https://lnkd.in/gxqQEqKX). I'm posting this just a few days after your talk, and I couldn't ignore today's release of Alphafold 3 (https://rdcu.be/dHkg8). I'm simultaneously intimidated and excited to see the quick development of these advanced structural biology tools! –Diogo PS: This will seminar was co-hosted by Celia Schiffer, Biochemistry and Molecular Biotechnology, and a great prelude to our upcoming biotech sessions in the Fall! We are just building the schedule with the aim of making something fresh with thought provokers from startups, academia, and industry! Do you have suggestions, want to give a talk, or help us organize it? Reach us! #nhprr

Can you imagine how to figure out which immunosuppressive therapies to use in this first? 🐷 🐒 We have contributed to an impressive total of 59 publications targeting CD40L and 52 publications targeting CD40 in NHP transplants that form the basis of this knowledge. 📖 👓 🎉

"Bring your Governor to Work" Day! A couple of weeks ago, we had a chance to share what we were doing to advance science with Massachusetts Governor Maura Healey. Governor Maura Healey visited Massachusetts Biomedical Initiatives (MBI), visited Nonhuman Primate Reagent Resource - NHPRR's beautiful new facilities, and gave a press conference on her proposed $1 billion reauthorization of the Life Sciences Initiative.

Fresh from the oven! Everything that you wanted to know but were afraid to ask about the performance of our lymphocyte-depleting antibody reagents! Key takeaway? Mine is: Antibody-mediated depletion is an active process that engages the immune system. Remember that when interpreting your study outcomes! 🐒 💉

Featuring our own Joanna Z. , and David Foehl!

🔬🌟 Welcome Aboard - Quality Management! 🌟 🔬 We're excited to welcome Vimala Gollamudi to lead our Quality efforts! Vimala joined our group to bring new expertise and perspectives to our operations. The new Quality unit, which will be led by her, will immediately add value to our products.  With a strong background in quality in drug development, Vimala is set to elevate our quality management standards and ensure that the best quality practices are followed in our research efforts. Thanks, Vimala, for adding your perspectives to our team! 🎉 #NewHire #Quality #Growth #Welcome

🌟🚀 Imagining the future of specialized biologicals from NHPRR As we embark on our 26th year, we're not just celebrating a milestone but imagining the future of biomedical research and our role in it. Our journey has been incredible, helping elucidate the role of major lymphocytes in infectious diseases and developing therapies that have supported transplants in primates for years. We are glad to participate in these contributions with the NHP scientific community. It's time to set our sights on the future! We are now re-imagining our processes and strategies to develop the next cycle of impactful, high-quality biological reagents! I promise there will be commitment, novelties, and innovations. I hope you join our collaborative efforts to advance science for the betterment of all! #NonhumanPrimateResource #FutureNHPRR #NHPRRKickoff #BiomedicalResearch #Innovation #Science #ScienceCommunity